Clinical Characteristics and Outcomes of 1894 Women with Peripartum Cardiomyopathy Treated with and Without Levosimendan in Germany
Journal of Cardiovascular Development and Disease · 09.03.2026 · 13 (3) · 126
DOI: 10.3390/jcdd13030126 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cardiovascular Development and Disease, online erschienen am 09.03.2026. Verfasst von Jan A Kloka und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anaesthesiology, Intensive Care Medicine and Pain Therapy, University Hospital, Goethe University Frankfurt, Theodor-Stern Kai 7, 60590…. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: internal institutional funding.
Abstract (Originalsprache)
Background
Peripartum cardiomyopathy (PPCM) is a rare form of heart failure occurring during the last month of pregnancy or within five months postpartum. While levosimendan is considered beneficial in heart failure and cardiogenic shock, evidence supporting its use in PPCM is limited. This study investigated the prevalence of PPCM in Germany and evaluated outcomes associated with levosimendan use.
Methods
Using national data from the German Statistical Office, all pregnant women diagnosed with PPCM and hospitalized between 2009 and 2022 were included. Patients were categorized into groups based on levosimendan treatment. Demographics, treatment modalities, peripartum complications, and transfusion rates were analyzed.
Results
The prevalence of PPCM in Germany is 0.01%; 3.60% of patients received levosimendan, mostly after childbirth (61.76%). Peripartum complications and the use of mechanical circulatory support devices were significantly higher in the levosimendan group (p < 0.0001). Women in the levosimendan group suffered significantly more often from intrapartum bleeding and increased rates of blood transfusion compared to women in the non-levosimendan group.
Conclusions
PPCM is a rare disease in Germany with a prevalence of 0.01%. Despite higher complication rates in women with levosimendan treatment, further studies are necessary to help determine the role and timing of levosimendan in the treatment of women with PPCM.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Anaesthesiology, Intensive Care Medicine and Pain Therapy, University Hospital, Goethe University Frankfurt, Theodor-Stern Kai 7, 60590 Frankfurt, Germany.
- Intensive Care, Emergency and Pain Medicine, Department of Anaesthesiology, University Hospital Würzburg, 97080 Wuerzburg, Germany.
ORCID-Profile: Jan A Kloka, Thomas Jasny, Armin Flinspach, Peter Kranke, Kai Zacharowski
Förderung
- internal institutional funding
Zitieren
APA
Kloka, J. A., Popescu, A., Friedrichson, B., Jasny, T., Blum, L. V., Noone, S., Flinspach, A., Kranke, P., Zacharowski, K., & Neef, V. (2026). Clinical Characteristics and Outcomes of 1894 Women with Peripartum Cardiomyopathy Treated with and Without Levosimendan in Germany. Journal of Cardiovascular Development and Disease, 13(3), 126. https://doi.org/10.3390/jcdd13030126
Vancouver
Kloka JA, Popescu A, Friedrichson B, Jasny T, Blum LV, Noone S, et al. Clinical Characteristics and Outcomes of 1894 Women with Peripartum Cardiomyopathy Treated with and Without Levosimendan in Germany. Journal of Cardiovascular Development and Disease. 2026;13(3):126. doi:10.3390/jcdd13030126
BibTeX
@article{Kloka2026,
author = {Kloka, Jan A and Popescu, Alexandra and Friedrichson, Benjamin and Jasny, Thomas and Blum, Lea V and Noone, Stephanie and Flinspach, Armin and Kranke, Peter and Zacharowski, Kai and Neef, Vanessa},
title = {Clinical Characteristics and Outcomes of 1894 Women with Peripartum Cardiomyopathy Treated with and Without Levosimendan in Germany},
journal = {Journal of Cardiovascular Development and Disease},
year = {2026},
volume = {13},
number = {3},
pages = {126},
doi = {10.3390/jcdd13030126}
}
EUVIMED